The FDA approval of Zurzuvae (zuranolone), the first oral medication, has offered new hope to mothers who have exhausted all other treatment options to cope with their postpartum depression. This is a milestone in recognizing the maternal mental health crisis that plagues our country. The benefit of this drug is that it offers a new
Zurzuvae: a beacon of hope for postpartum depression or a superficial solution? originally appeared in KevinMD.com.
